• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

    11/4/24 11:16:33 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BHVN alert in real time by email
    SC 13G/A 1 UnitedStates_13G__BiohavenLt.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Biohaven Ltd (Title of Class of Securities) Common Stock (CUSIP Number) G1110E107 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. G1110E107 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 137,290 (7) Sole dispositive power 7,567,951 (8) Shared dispositive power 217,958 (9) Aggregate amount beneficially owned by each reporting person 7,785,909 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 8.23% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Biohaven Ltd Item 1(b) Address of issuer's principal executive offices: 215 Church Street New Haven, CT 06510 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: G1110E107 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 7,785,909 (b) Percent of class: 8.23% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 7,785,909 (b) Percent of class: 8.23% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 137,290 (iii) Sole power to dispose or to direct the disposition of: 7,567,951 (iv) Shared power to dispose or to direct the disposition of: 217,958 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Pare
    Get the next $BHVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BHVN

    DatePrice TargetRatingAnalyst
    2/11/2025$65.00Buy
    Deutsche Bank
    9/16/2024$57.00Buy
    Jefferies
    9/4/2024$55.00Outperform
    Bernstein
    7/24/2024$58.00Overweight
    Morgan Stanley
    2/16/2024$62.00Outperform
    RBC Capital Mkts
    2/6/2024$59.00Buy
    UBS
    12/22/2023$50.00Buy
    H.C. Wainwright
    12/8/2023$58.00Outperform
    Robert W. Baird
    More analyst ratings

    $BHVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Antonijevic Irina

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/7/25 5:16:02 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Heffernan Michael Thomas

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/7/25 5:15:04 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bailey Gregory

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/7/25 5:14:32 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biohaven Announces Investment up to $600 Million by Oberland Capital

      Up to $600 million in non-dilutive capital in exchange for capped milestone and royalty payments on future troriluzole product net sales$250 million to be funded at closing$150 million available at the Company's option upon the achievement of regulatory milestones related to troriluzole Up to $200 million at the mutual agreement of the parties for permitted strategic acquisitions and related costs and expensesNEW HAVEN, Conn., April 28, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseas

      4/28/25 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting

      SAN DIEGO and NEW HAVEN, Conn., April 5, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) announced today that it will present 13 abstracts at the 2025 American Academy of Neurology (AAN) Annual Meeting, taking place from April 5 to April 9, 2025 in San Diego, California. The presentations highlight Biohaven's innovative neuroscience pipeline across multiple early and late-stage development programs including Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation. Irfan Qureshi, M.D., Chief Medical Officer

      4/5/25 9:00:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Deutsche Bank initiated coverage on Biohaven with a new price target

      Deutsche Bank initiated coverage of Biohaven with a rating of Buy and set a new price target of $65.00

      2/11/25 7:01:45 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Biohaven with a new price target

      Jefferies initiated coverage of Biohaven with a rating of Buy and set a new price target of $57.00

      9/16/24 7:22:04 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bernstein initiated coverage on Biohaven with a new price target

      Bernstein initiated coverage of Biohaven with a rating of Outperform and set a new price target of $55.00

      9/4/24 7:31:23 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BHVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Director Childs John W bought $996,238 worth of shares (32,700 units at $30.47) (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      3/5/25 7:01:52 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Childs John W bought $2,999,970 worth of shares (73,170 units at $41.00) (SEC Form 4)

      4/A - Biohaven Ltd. (0001935979) (Issuer)

      3/5/25 6:59:47 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Childs John W bought $1,042,393 worth of shares (29,000 units at $35.94) (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      12/31/24 7:00:14 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

      SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

      11/14/24 3:06:46 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

      SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

      11/12/24 1:20:24 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

      SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

      11/4/24 11:16:33 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    Financials

    Live finance-specific insights

    See more
    • Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

      Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes.Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.Troriluzole achieved statistically significant superiority on 9 consecutive, prespecified primary and secondary endpoints.SCA patients treated with troriluzole showed a 50-70% slowing of disease progression, representing 1.5-2.2 years delay in disease progression over the 3-year study period.Biohaven plans to submit a New Drug Application (NDA)

      9/23/24 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

      Conference call and webcast to be held Monday, September 23, at 8:30am ET  NEW HAVEN, Conn., Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE (NCT06529146), a study designed in discussion with the US Food and Drug Administration (FDA), to assess the effectiveness of troriluzole in Spinocerebellar Ataxia. Conference Call and Webcast DetailsBiohaven will hold a live conference call and webcast Monday, September 23, 2024, at 8:30 a.m. Eastern Time. The live e

      9/20/24 7:09:00 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders

      Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2/JAK3 inhibitorsExclusive license covers global rights excluding China regionBiohaven anticipates initiating Phase 1 clinical development in 2023NEW HAVEN, Conn., March 22, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. BHV-8000 (previously TLL-041) was

      3/22/23 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    SEC Filings

    See more
    • Biohaven Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Biohaven Ltd. (0001935979) (Filer)

      5/7/25 5:18:11 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Biohaven Ltd. (0001935979) (Filer)

      4/28/25 7:59:17 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Biohaven Ltd.

      DEFA14A - Biohaven Ltd. (0001935979) (Filer)

      3/18/25 4:48:49 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

      HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

      7/1/24 7:00:00 AM ET
      $BHVN
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments

      Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug AdministrationTaldefgrobep alfa granted Fast Track Designation in SMADriving strong and consistent progress across six robust drug development platforms in 2023:in Kv7 activation, targeting Phase 2/3 study start in focal epilepsy and bipolar disorder in the second half of 2023;Phase 1 study initiation planned with potentially fi

      5/12/23 4:30:00 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care